Aura Biosciences, Inc. · NASDAQ:AURA
Aura Biosciences — Corporate Update (August 2026)
21 slides from Aura Biosciences's corporate update, Aug 11, 2026
Slide 1: A Focused Vision: Targeted Therapy to Transform Ocular Cancer Care
Exhibit 99.2 August 2026 A Focused Vision: Targeted Therapy to Transform Ocular Cancer Care
Slide 2: Legal Disclosure
Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may", "anticipate", "believe", "co
Slide 3: Aura is Positioned to Become the Global Leader in Ocular Oncology
Aura is well-positioned to become the leader in ocular oncology Aura is Positioned to Become the Global Leader in Ocular Oncology Transform the Treatment Paradigm in Early Choroidal Melanoma Potential to deliver the first curative, vision-preserving therapy in early choroidal melanoma Patients face
Slide 4: Ocular Oncology: High Unmet Need with No Vision-Sparing Therapies
a Includes conjunctival melanoma, primary acquired melanosis, squamous cell carcinoma and ocular surface squamous neoplasia.1-5 1. Yu G-P, et al. Am J Ophthalmol. 2003;135(6):800–6. 2. Triay E, et al. Br J Ophthalmol. 2009;93(11):1524–8. 3. Newton R, et al. Lancet. 1996;347(9013):1450–1. 4. Dalvin L
Slide 5: Clinical Pipeline Across Ocular Oncology
PoC, proof-of-concept. ClinicalTrial.gov identifiers: phase 3 choroidal melanoma (CoMpass) NCT06007690; phase 2 metastases to the choroid NCT06643884. Clinical Pipeline Across Ocular Oncology Program Preclinical Phase 1 Phase 2 Phase 3 Early Choroidal melanoma Metastases to the Choroid Cancers of th
Slide 6: A Novel, Targeted Therapeutic Modality
DLT, dose-limiting toxicity; MoA, mechanism of action; NMIBC, non-muscle-invasive bladder cancer; SAE, serious adverse event; VLP, virus-like particle. A Novel, Targeted Therapeutic Modality Unique tumor selectivity VLP-drug conjugate targets a key receptor molecule expressed in the early stages of
Slide 7: Bel-sar's Dual Mechanism of Anti-Tumor Activity
Bel-sar’s Dual Mechanism of Anti-Tumor Activity Pro-immunogenic necrosis leads to T cell activation and immune-mediated tumor cell killing Kines RC, et al. Int J Cancer. 2016;138(4):901–11. Kines RC, et al. Mol Cancer Ther. 2018;17(2):565–74. Kines RC, et al. Cancer Immunol Res. 2021;9:693–706. Bel-
Slide 8: Bel-sar is Administered as a Targeted In-Office Procedure
Bel-sar is Administered as a Targeted In-Office Procedure with the Potential for Durable Benefit Bel-sar, belzupacap sarotalocan. No radiation- related morbidity Vision preservation Local tumor control Reduce metastasis risk with early treatment Improve safety and quality of life Two injections (2 m
Slide 9: Bel-sar: Potentially Frontline Vision-Sparing Treatment for Largest CM Patient Segment
a Each figure represents ~250 persons. 1. Singh AD, et al. Ophthalmology. 2005;112(10):1784–89 (U.S. population). 2. Shields CL, et al. Choroidal and ciliary body melanoma. Available at: https://eyewiki.aao.org/Choroidal_and_Ciliary_Body_Melanoma Accessed September 9, 2024. 3. Epidemiology analysis
Slide 10: Phase 2 Trial In Early Choroidal Melanoma
Subtherapeutic and therapeutic dose ranges determined via post-hoc analysis One cycle = Doses on days 1, 8, and 15. a 12 patients enrolled, 1 patient who discontinued after 1 cycle due to unrelated SAEs is not included in data analysis (n=11). b Cohort 2:2 participants were planned; third participan
Slide 11: Bel-sar has Demonstrated a Favorable Safety Profile
Bel-sar has Demonstrated a Favorable Safety Profile No posterior inflammation No treatment-related SAEs No grade 3–5 treatment-related AEs * Table presents participants with AEs related to bel-sar or laser by severity and overall; participants with >1 AE are counted in the highest severity group. AE
Slide 12: High Local Complete Response Rate at 12 Months Follow-Up
High Local Complete Response Rate at 12 Months Follow-Up 80% tumor control ratea at 12 months among the 10 phase 3-eligible patients in the 3-cycle cohorts a Local complete response, or CR, in early-stage choroidal melanoma is described as tumor control and complete arrest of tumor growth by ocular
Slide 13: Rate of Tumor Growth with Bel-sar Treatment
Rate of tumor growth ± SE, mm/yr P < 0.0001 Rate of Tumor Growth with Bel-sar Treatment In Phase 3-Eligible Patients, the 3-Cycle Regimen Resulted in Cessation of Growth Among Responders (N=8) Tumor thickness growth rates/slopes estimated using Mixed Models for Repeat Measures (MMRM); random interce
Slide 14: Visual Acuity Was Preserved in 90% of Phase 3-Eligible Patients
Median Change in BCVA in Phase 3-Eligible Participants with Therapeutic Regimen (N=10)a Visual Acuity Was Preserved in 90% of Phase 3-Eligible Patients Receiving a Bel-sar Therapeutic Regimen 80% were at high risk of vision loss with tumors < 3 mm to the fovea or optic nerve 90% visual acuity preser
Slide 15: Phase 3 Registration Study is Fully Enrolled
a Early choroidal melanoma, small choroidal melanoma or indeterminate lesions. b 40 µg bel-sar arm included for masking; excluded from statistical analysis. bel-sar, belzupacap sarotalocan; BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; FDA, United State Food
Slide 16: Phase 3 CoMpass Trial is Highly Powered for Success Based on Phase 2 Results
Phase 3 CoMpass Trial is Highly Powered for Success Based on Phase 2 Results Kaplan-Meier Simulation of Time-to-Event Endpoints Using Phase 2 Data Study duration 12 months. Participants either had an event or were censored at the last visit; some had their Week 52 visit after 365 days. Any events at
Slide 17: Bel-sar Has a Significant Commercial Opportunity in Additional Ocular Oncology Indications
a Includes conjunctival melanoma, primary acquired melanosis, squamous cell carcinoma and ocular surface squamous neoplasia.2-6 1. Epidemiology analysis for choroidal melanoma and choroidal metastasis by ClearView Healthcare Partners and Putnam. 2. Yu G-P, et al. Am J Ophthalmol. 2003;135(6):800-6.
Slide 18: Aura is Positioned to Become the Global Leader in Ocular Oncology
Aura is well-positioned to become the leader in ocular oncology Aura is Positioned to Become the Global Leader in Ocular Oncology Advancing the development of bel-sar in ocular oncology Under current operating plan, expected cash runway is into 1H 2029 Opportunity to build a durable leadership posit
Slide 19: Appendix
Appendix
Slide 20: Baseline Characteristics
Baseline Characteristics All Study Participants a High risk for vision loss defined as tumor edge within either 3 mm of foveal center or 3 mm of optic disc edge. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; LBD, largest basal diameter. Data on file, Aura Bio
Slide 21: Phase 2 Data Support Phase 3 Assumptions
Bel-sar, belzupacap sarotalocan. ClinicalTrials.gov Identifier, NCT06007690; AU-011-301. Phase 2 Data Support Phase 3 Assumptions Phase 3 trial design P < 0.005 93% power (Δ20) Actual data (Δ60) >99% power P < 0.05 Robustness Analysis of Tumor Control Rates Overall rate in phase 2 2x “worse” than ph